Company: PRME
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023486
Chunk: 25

Company: Prime Medicine, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
Item 1. Financial Statements (unaudited)

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share amounts)March 31,2025December 31,2024AssetsCurrent assets:Cash and cash equivalents$91,877 $182,476 Short-term investments48,467 2,998 Short-term investment — related party3,912 4,968 Collaboration receivable — related party17 — Prepaid expenses2,948 6,777 Other current assets16,544 14,667 Total current assets163,765 211,886 Property and equipment, net24,956 24,404 Operating lease right-of-use assets125,380 47,156 Restricted cash14,062 14,062 Total assets$328,163 $297,508 Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$10,025 $11,351 Accrued expenses and other current liabilities9,191 15,904 Deferred revenue — related party8,214 7,092 Operating lease liability6,858 3,614 Total current liabilities34,288 37,961 Deferred revenue, net of current — related party60,658 63,218 Operating lease liability, net of current114,293 37,180 Research and development funding liability12,000 6,000 Total liabilities221,239 144,359 Commitments and contingenciesStockholders’ equityCommon stock, par value of $0.00001 per share; 775,000,000 shares authorized; 131,160,842 and 131,160,842 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively2 2 Additional paid-in capital846,039 840,358 Accumulated other comprehensive loss(15)1 Accumulated deficit(739,102)(687,212)Total stockholders’ equity106,924 153,149 Total liabilities and stockholders’ equity$328,163 $297,508 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Three Months